©The Author(s) 2025.
World J Gastroenterol. Nov 7, 2025; 31(41): 111745
Published online Nov 7, 2025. doi: 10.3748/wjg.v31.i41.111745
Published online Nov 7, 2025. doi: 10.3748/wjg.v31.i41.111745
Table 2 Association between human leukocyte antigen alleles and immunogenicity, %
| HLA | Anti-infliximab antibody (-) (n = 19) | Anti-infliximab antibody (+) (n = 19) | P value |
| HLA-C*03:04:01 | 0 | 31.6 | 0.02 |
| HLA-DQA1*05 | 36.8 | 52.6 | 0.328 |
| HLA | Anti-adalimumab antibody (-) (n = 17) | Anti-adalimumab antibody (+) (n = 3) | |
| HLA-B*15:18:01 | 0 | 66.7 | 0.016 |
| HLA-DQA1*05 | 52.9 | 66.7 | 1.000 |
- Citation: Weng MT, Yao CY, Lin WC, Lai SK, Tung CC, Wang CY, Wong JM, Chen PL, Wei SC. HLA-C*03:04:01 and HLA-B*15:18:01 but not HLA-DQA1*05 associated with anti- tumor necrosis factor antibody formation in Taiwanese inflammatory bowel disease patients. World J Gastroenterol 2025; 31(41): 111745
- URL: https://www.wjgnet.com/1007-9327/full/v31/i41/111745.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i41.111745